# US 2021/0260148 A1 · Peptides for treating mucosa

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260148 A1
- Document ID: US20210260148A1
- Status: Published application
- Kind: A1
- Application number: 17/249,119
- Filed: 2021-02-21
- Published: 2021-08-26
- Earliest claimed: 2020-02-21
- Inventors: Jean CARRUTHERS
- Web page: https://patentgrep.com/patent/US20210260148A1

## CPC

- A61K 38/06: Tripeptides
- A61K 38/05: Dipeptides
- A61K 38/07: Tetrapeptides
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 9/0031: {Rectum, anus}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/0043: {Nose}
- A61K 9/0046: {Ear}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and methods for treating mucosa using compositions containing two or more peptides are described herein. The compositions can be used to treat various diseases associated with mucosa of the mouth, eye, ear, nose, esophagus, stomach, small intestinal, large intestine, rectum, vagina, urethra, penis, uterus, and the like and combinations thereof.

## Claims

### Claim 1

A composition for treating mucosa, comprising:
about 1 parts per million (ppm) to about 10 ppm tripeptide-1 and one or more dipeptide, tripeptide, tetrapeptide, or combinations thereof; and
about 1 ppm to about 10 ppm hexapeptide-12 and a hexapeptide with amino acid sequence different from the hexapeptide-12.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition is aqueous.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising one or more additional ingredients selected from the group consisting of disodium EDTA, niacinamide, caprylyl glycol, caprylhydroxamic acid, glycerin, phenoxyethanol, ethylhexylglycerin, betaine, propanediol, phospholipids, isopropyl palmitate, lecithin, polyacrylate-13, polysorbate 20, Squalane, Dunaliella Salina extract, phytosterols, Olea Europaea fruit oil, hydrolyzed pea protein, Butyrospermum Parkii (Shea) Butter, ceramide NP, tocopherol, butylene glycol, caprylyl methicone, ascorbyl palmitate, phosphatidylserine, and combinations thereof.

### Claim 4 (depends on 1)

The composition of claim 1, further comprising about 0.01 weight % to about 5.0 weight % phosphatidylserine based on the total weight of the composition.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the tripeptide-1 is selected from the group consisting of palmitoyl tripeptide-1, myristoyl tripeptide-1, and combinations thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the hexapeptide-12 is selected from the group consisting of palmitoyl hexapeptide-12, myristoyl hexapeptide-12, and combinations thereof.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising about 1 ppm to about 10 ppm tetrapeptide.

### Claim 8

A method for treating mucosa, comprising administering to a patient in need of treatment a composition including:
about 1 parts per million (ppm) to about 10 ppm tripeptide-1 and one or more dipeptide, tripeptide, tetrapeptide, or combinations thereof; and
about 1 ppm to about 10 ppm hexapeptide-12 and a hexapeptide with amino acid sequence different from the hexapeptide-12.

### Claim 9 (depends on 8)

The method of claim 8, wherein the composition further comprises about 0.01 weight % to about 5.0 weight % phosphatidylserine based on the total weight of the composition.

### Claim 10 (depends on 8)

The method of claim 8, wherein the tripeptide-1 is selected from the group consisting of palmitoyl tripeptide-1, myristoyl tripeptide-1, and combinations thereof.

### Claim 11 (depends on 8)

The method of claim 8, wherein the hexapeptide-12 is selected from the group consisting of palmitoyl hexapeptide-12, myristoyl hexapeptide-12, and combinations thereof.

### Claim 12 (depends on 8)

The method of claim 8, further comprising about 1 ppm to about 10 ppm tetrapeptide.

### Claim 13 (depends on 8)

The method of claim 8, wherein the composition further comprises one or more additional ingredients selected from the group consisting of disodium EDTA, niacinamide, caprylyl glycol, caprylhydroxamic acid, glycerin, phenoxyethanol, ethylhexylglycerin, betaine, propanediol, phospholipids, isopropyl palmitate, lecithin, polyacrylate-13, polysorbate 20, Squalane, Dunaliella Salina extract, phytosterols, Olea Europaea fruit oil, hydrolyzed pea protein, Butyrospermum Parkii (Shea) Butter, ceramide NP, tocopherol, butylene glycol, caprylyl methicone, ascorbyl palmitate, phosphatidylserine, and combinations thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein the mucosa is oral mucosa and the patient is in need of treatment for gingivitis, mucosal lesions, periodontal disease, gum stomatitis, oral ulcers, oral candidiasis, oral lichen planus, mucous membrane pemphigoid, mucosal pemphigus vulgaris, chronic aphthous stomatitis, glossitis, oral herpes, cold sores, lesions or ulcers in the oral cavity, and combinations thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the mucosa is nasal mucosa and the patient is in need of treatment for allergic rhinitis, hay fever, vasomotor rhinitis, non-allergic eosinophilic rhinitis, chronic sinusitis, inflammation of the paranasal sinuses, nasal polyps, eczematous nasal vestibulitis, epistaxis, inflammatory diseases associated with the nasal cavity, and combinations thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the mucosa is vaginal mucosa and the patient is in need for treatment of atrophic vaginitis, cervical ectropia, follicular vulvitis, erythematous vulvitis, radiation-related vulvitis, genital herpes, increase vaginal lubrication, improve sexual arousal, and maintain elasticity of vaginal tissues after menopause, and combinations thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the mucosa is rectal mucosa and the patient is in need of treatment for rectal pruritus, faecal incontinence, ulcerative proctitis, rectal prolapse, genital herpes, and combinations thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein the mucosa is ocular mucosa, and the patient is in need of treatment for conjunctiva, keratoconjunctivitis sicca or anaphylaxis conjunctivitis, fungal infection, viral infection, bacterial infection, and combinations thereof.

### Claim 19 (depends on 1)

The method of claim 1, wherein the mucosa is aural mucosa, and the patient is in need of treatment for earache, otitis media, otitis externa, ear infections, chronic otitis, meniere's disease, tinnitus, cerumen impaction, acoustic neuroma, mastoiditis, benign paroxysmal positional vertigo (BPPV), cholesteatoma, and combinations thereof.

### Claim 20 (depends on 1)

The method of claim 1, wherein the mucosa is intestinal mucosa, and the patient is in need of treatment for Crohn's disease, ulcerative colitis, irritable bowel syndrome, celiac disease, herpetic dermatitis.
